Elektrofi

Based in the US, Elektrofi, Inc. is a biotech company focused on enhancing drug delivery systems through its innovative microparticle technology, facilitating effective administration of biologic therapies. Elektrofi, Inc. specializes in advanced drug delivery solutions.

Founded in 2016 and headquartered in Boston, US, the company has successfully completed 5 deals. It recently received funding through a TRADE SALE, raising USD 750. 00 mn from Halozyme, Inc. , which will leverage its technologies for expanded applications in the life sciences sector.

Founders Chase Coffman and Jason Norris bring extensive expertise in biotechnology and pharmaceuticals to the company. Elektrofi offers proprietary Hypercon™ technology that revolutionizes the delivery of biologic therapies through hyper-concentration microparticles. Their platform focuses on subcutaneous delivery, allowing patients to administer treatments at home rather than relying on intravenous methods. The technology caters to pharmaceutical partners and healthcare providers addressing chronic diseases including cancer and autoimmune disorders, with distribution extensively across North America, Europe, and Asia.

Elektrofi generates revenue primarily through strategic partnerships and licensing agreements with pharmaceutical companies utilizing its Hypercon™ technology. These agreements include milestone payments and royalties based on the commercial success of the developed therapies. Revenue is augmented by ongoing collaborations aimed at next-generation medicines, ensuring a consistent income stream as products progress through clinical development and market entry. Looking ahead, Elektrofi plans to launch new innovations leveraging its microparticle technology in the coming years.

The company is targeting expansions into international markets, particularly in Europe and Asia, by 2026. The recent acquisition by Halozyme, Inc. for USD 750 mn, along with potential additional milestone payments, will support the integration of Elektrofi's technology into Halozyme's portfolio, facilitating further development and commercialization of advanced drug delivery systems.